

BROLUCIZUMAB injection (Beovu® ▼) for diabetic macular oedema

The Pan Mersey Area Prescribing Committee recommends the prescribing of BROLUCIZUMAB injection (Beovu® ▼), by specialists only, for diabetic macular oedema in accordance with NICE TA820.

RED

Brolucizumab is licensed for the treatment of visual impairment due to diabetic macular oedema.¹

[Nice technology appraisal \(TA\) 820](#) (31 August 2022) recommends brolucizumab as an option for treating visual impairment due to diabetic macular oedema in adults, only if:

- > the eye has a central retinal thickness of 400 micrometres or more at the start of treatment.²

Brolucizumab should be prescribed and administered by ophthalmology specialist teams. Prescribing and monitoring should be retained by the specialist.

Costing information

The manufacturer has agreed to provide brolucizumab according to a commercial arrangement making treatment with brolucizumab similar in cost to treatment with other suitable treatments. If patients and their clinicians consider brolucizumab to be one of a range of suitable treatments (including aflibercept and ranibizumab) they should choose the least expensive treatment option, taking account of administration costs, dosage, price per dose and commercial arrangements.²

NICE does not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or £9,000 per 100,000 population). This is because brolucizumab is a further treatment option and is available at a similar price to the current treatment options.

References

1. Novartis Pharmaceuticals UK Ltd. Summary of Product Characteristics, [Beovu 120 mg/ml solution for injection in pre-filled syringe](#); May 2022. Accessed 12 August 2022.
2. National Institute for Health and Care Excellence. Technology Appraisal 820: Brolucizumab for treating diabetic macular oedema, 31 August 2022. Accessed 31 August 2022.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.